CVS Health shares rise after Q1 beat, as investors weigh whether the momentum can last

CVS Health’s (CVS) recent run higher is drawing fresh attention from investors who are trying to gauge whether the gains seen since the company’s last earnings report can continue. In a market update dated June 5, Zacks Equity Research noted that it had been roughly a month since CVS reported first-quarter results and that the stock had added about 8.5% over that period, outperforming the S&P 500. The core question now, as the next reporting window approaches, is how much of that move was driven by fundamentals versus expectations for what comes next.

CVS’s latest results came on May 6, when the company reported first-quarter 2026 results and lifted its outlook. In the quarter ended March 31, CVS posted adjusted earnings per share of $2.57, beating the Zacks Consensus Estimate of $2.21, according to Zacks. Total revenues were $100.4 billion, up 6.2% year over year and above a consensus revenue mark cited by Zacks at $94.37 billion. CVS also reported GAAP diluted EPS of $2.30 for the quarter.

The earnings strength was broad across CVS’s operating segments. Zacks reported that Health Services revenue rose to $48.24 billion, up 11% year over year, driven by pharmacy drug mix and brand inflation. Health Care Benefits revenue increased to $35.97 billion, up 3.3%, supported by strength in the Government business. Pharmacy & Consumer Wellness revenue was essentially flat at $31.99 billion, with prescription growth and mix benefits offset by regulatory-related price reductions and reimbursement pressure.

CVS also highlighted operating leverage in the quarter. Operating income rose to $4.68 billion, up 38.7% year over year, and operating margin improved to 4.7%, based on Zacks’ recap. Adjusted operating income increased 12.5% to $5.15 billion, and gross margin expanded to 15.6%. On the cash and balance sheet side, Zacks said CVS ended the quarter with $9.54 billion in cash and cash equivalents and repaid $1.52 billion of long-term debt during the period. The company also paid $847 million in dividends and reported long-term debt of $60.53 billion as of March 31, 2026.

Guidance was a central driver of investor optimism. CVS raised its full-year 2026 targets, lifting its GAAP diluted EPS range to $6.24 to $6.44 from $5.94 to $6.14, and its adjusted EPS guidance range to $7.30 to $7.50 from $7.00 to $7.20. It also increased cash flow from operations guidance to at least $9.5 billion, up from at least $9.0 billion. The company said the update reflects increases in the Health Care Benefits and Pharmacy & Consumer Wellness segments, while maintaining a cautious view for the rest of the year due to elevated cost trends and potential macro headwinds.

Looking ahead, Zacks said estimates had trended upward over the prior month and cited a Zacks Consensus Estimate for adjusted EPS in 2026 of $7.14. The next corporate update is expected around late July based on MarketBeat’s estimates, with a cited next earnings date of July 30, 2026. Since CVS has not framed its outlook as guaranteeing near-term results beyond the annual guidance, investors will likely focus on whether the margin and cost progress seen in the quarter can be sustained through the next reporting period.

One caveat is that the June 5 market commentary does not provide a detailed breakdown of what portion of the share move can be attributed to estimate changes versus broader market conditions, and it does not disclose incremental guidance beyond what CVS already published with its raised 2026 targets. CVS’s own release emphasized continued momentum and pointed to operational initiatives, including progress on prior authorization reform at Aetna and improved Medicare Advantage rate notice and home health assessment policy for 2027, but it also reiterated that costs remain elevated. The next earnings report will be the clearest check on whether the raised targets remain credible as cost trends and reimbursement dynamics evolve.